Friday, February 12, 2021 7:31:44 PM
Also, the NK cells do not express a detectable level of CIS protein.
The NK cells are further genetically engineered to express a reduced level of a transforming growth factor beta receptor.
The NK cells are further genetically edited to express a reduced level of B2M.
The NK cells are further genetically edited to express a reduced level of CIITA.
The NK cells are further genetically edited to express a reduced level of NKG2A receptor.
The NK cells are further genetically edited to express a reduced level of a Cbl proto-oncogene B protein encoded by a CBLB gene.
The NK cells are further genetically edited to express a reduced level of a tripartite motif-containing protein 29 protein encoded by a TRIM29 gene.
The NK cells are further genetically edited to express a reduced level of a suppressor of cytokine signaling 2 protein encoded by a SOCS2 gene.
The NK cells are further genetically edited to express CD47.
The NK cells are further genetically engineered to express HLA-E.
The NK cells are further genetically edited to disrupt expression of at least one immune checkpoint protein by the NK cells (CTLA4, PD-1, LAG-3, NKG2A receptor, KIR2DL-1, KIR2DL-2, KIR2DL-3, KIR2DS-1 and/or KIR2DA-2, and combinations thereof).
Moving on,
The T-cells comprise at least one genetically edited subunit of a TCR (alpha), or TCR KO, such that they do not exhibit alloreactive effects against cells of a recipient subject.
The T-cells are further genetically edited to reduce expression of one or more of CIS, TGFBR, B2M, and CIITA as compared to non-engineered T cells, or to express CD47 or HLA-E.
The T-cells are further genetically edited to reduce expression of one or more of TRIM29 and SOCS2.
The T-cells are further genetically edited to disrupt expression of at least one immune checkpoint protein, wherein the at least one immune checkpoint protein is selected from CTLA4, PD-1, and LAG-3.
Recent NKTX News
- Nkarta to Participate in Upcoming Investor Conference • GlobeNewswire Inc. • 09/03/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2024 08:30:04 PM
- Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights • GlobeNewswire Inc. • 08/14/2024 01:03:42 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:08:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:05:18 PM
- Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights • GlobeNewswire Inc. • 08/13/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:48:13 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:47:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 08:45:43 PM
- Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus • GlobeNewswire Inc. • 07/24/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 10:30:13 AM
- Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President • GlobeNewswire Inc. • 07/16/2024 10:01:00 AM
- Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications • GlobeNewswire Inc. • 06/27/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:10:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:07:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:07:22 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:04:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:22:58 PM
- Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors • GlobeNewswire Inc. • 06/13/2024 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:14:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:04:53 PM
- Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights • GlobeNewswire Inc. • 05/09/2024 08:01:00 PM
- Nkarta to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 04/03/2024 08:02:00 PM
- Nkarta Announces Pricing of $240 Million Underwritten Offering • GlobeNewswire Inc. • 03/25/2024 10:30:00 AM
- Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights • GlobeNewswire Inc. • 03/21/2024 08:01:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM